Literature DB >> 15615493

Heritable disorders of the RANKL/OPG/RANK signaling pathway.

Michael P Whyte1, Steven Mumm.   

Abstract

Figure 7 summarizes the heritable disorders identified to date that directly involve the RANKL/OPG/RANK signaling pathway in humans. Activating mutations in TNFRSF11A encoding RANK and deactivating mutations in TNFRSF11B encoding OPG cause systemic bone disease (FEO, PDB2, ESH and JPD) featuring accelerated bone turnover, low bone mass, deafness early in life, and loss of dentition by enhancing signaling. No human disease has been identified involving defects in the TNFSF11 gene encoding RANKL. Despite genetic bases for these autosomal dominant and recessive conditions involving bone cell receptors, focal expansile osteolytic lesions are common and can occur perhaps from further local activation of osteoclast-mediated bone resorption following trauma. These disorders resemble PDB which can be inherited as an autosomal dominant trait with focal osteolytic disease, sometimes with deafness and tooth loss, and increasingly associated with mutations, but in other genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615493

Source DB:  PubMed          Journal:  J Musculoskelet Neuronal Interact        ISSN: 1108-7161            Impact factor:   2.041


  17 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

2.  RANK overexpression as a novel esophageal cancer marker: validated immunohistochemical analysis of two different ethnicities.

Authors:  Xiaobin Cui; Hao Peng; Jing Jin; Tingting Li; Shumao Zhang; Tingting Jin; Su Li; Chunxia Liu; Weihua Liang; Feng Li; Yunzhao Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  Multicentric carpotarsal osteolysis syndrome is caused by only a few domain-specific mutations in MAFB, a negative regulator of RANKL-induced osteoclastogenesis.

Authors:  Steven Mumm; Margaret Huskey; Shenghui Duan; Deborah Wenkert; Katherine L Madson; Gary S Gottesman; Angela R Nenninger; Ronald M Laxer; William H McAlister; Michael P Whyte
Journal:  Am J Med Genet A       Date:  2014-07-02       Impact factor: 2.802

4.  Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvitamin D3 is mediated through multiple long-range enhancers.

Authors:  Sungtae Kim; Miwa Yamazaki; Lee A Zella; Nirupama K Shevde; J Wesley Pike
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

Review 5.  RANKL/RANK-beyond bones.

Authors:  Reiko Hanada; Toshikatsu Hanada; Verena Sigl; Daniel Schramek; Josef M Penninger
Journal:  J Mol Med (Berl)       Date:  2011-03-29       Impact factor: 4.599

Review 6.  RANKL/OPG; Critical role in bone physiology.

Authors:  T John Martin; Natalie A Sims
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 7.  Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:  David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey
Journal:  Nat Rev Drug Discov       Date:  2012-05       Impact factor: 84.694

Review 8.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

Review 9.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases.

Authors:  J L Sottnik; E T Keller
Journal:  Curr Mol Med       Date:  2013-05       Impact factor: 2.222

Review 10.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.